Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Janone Inc JAN

Industrials
JanOne Inc. is a clinical-stage pharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is an oral pharmaceutical composition of sodium nitrite that targets poor blood flow to... see more

Recent & Breaking News (NDAQ:JAN)

JanOne Regains Compliance with Nasdaq's Listing Requirements

PR Newswire March 15, 2024

JanOne to Present at the Dawson James 8th Annual Investment Conference

PR Newswire September 21, 2023

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

PR Newswire August 31, 2023

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

PR Newswire August 29, 2023

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

PR Newswire August 25, 2023

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire August 22, 2023

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire August 18, 2023

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

PR Newswire August 18, 2023

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

PR Newswire June 28, 2023

JanOne Completes Pre-IND Meeting with FDA on Jan123

PR Newswire April 18, 2023

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

PR Newswire April 13, 2023

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

PR Newswire March 24, 2023

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

PR Newswire March 23, 2023

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

PR Newswire March 23, 2023

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

PR Newswire March 22, 2023

JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

PR Newswire February 22, 2023

JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

PR Newswire January 26, 2023

JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

PR Newswire January 10, 2023

JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

PR Newswire September 16, 2022

ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

PR Newswire July 5, 2022